Search

everythinglearnresearchcommunity

for

Search:↓

Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.

Golvatinib shows promise as a treatment for Omicron in elderly patients.

NSC167409 can effectively inhibit the virus causing hand, foot, and mouth disease.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Hydroxychloroquine, nitazoxanide, and ivermectin were similarly effective in treating early COVID-19.

Plant compounds may boost antiviral treatments.

Early treatment with azithromycin and other drugs reduced COVID-19 symptoms and complications.

Researchers found several compounds that could potentially treat Zika virus.

The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.

Cepharanthine effectively reduces Herpes Simplex Virus Type 1 by blocking certain cell pathways and promoting cell death.

The document concludes that drug repurposing, which is reusing known medicines for new illnesses, can provide faster, cheaper treatment options for various serious diseases, including cancer, COVID-19, and rare diseases.

Common dermatology drugs were considered but are controversial for COVID-19 treatment.

Early treatment with azithromycin and other drugs reduced COVID-19 symptoms and complications.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

Certain alkaloids could help create new coronavirus drugs.

A new delivery system makes Curcumin more effective and safer against viruses.

New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.

Some gonadal hormone drugs can block filovirus entry into cells.

Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Cepharanthine analogues, especially tetrandrine, show potential for treating COVID-19.

Bromhexine and spironolactone together reduced COVID-19 symptoms and hospitalization time without side effects.

Early detection, prevention, and proper management can reduce TB-IRIS complications and deaths in HIV patients.

Two existing drugs may help treat COVID-19 by inhibiting a key viral protein.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

The document concludes that reactivation of herpesviruses, especially HHV-6, is linked to severe symptoms and complications in drug-induced hypersensitivity syndrome.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.